Pharmaceutical

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval

Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.

Jun 20, 2024 - 04:00
Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval
Anti-RANKL Monoclonal Antibody is under clinical development by Jiangsu Pacific Meinuoke Bio-Pharmarceutical and currently in Phase I for Osteoporosis.
Read the original article

Tags:

Previous Article

ILution travoprost by Glaukos for Ocular Hypertension: Likelihood of Approval

Next Article

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Hipra’s Covid-19 booster gets EMA nod and enters an uncertain landscape

Hipra’s Covid-19 booster gets EMA nod and enters an unc...

Mar 31, 2023

ALS advocates say criticism of new drugs misses bigger picture

ALS advocates say criticism of new drugs misses bigger ...

Sep 8, 2023

STAT+: Better Therapeutics data on apps’ benefit with GLP-1s, Orexo hits a snag

STAT+: Better Therapeutics data on apps’ benefit with G...

Oct 12, 2023